TY - JOUR
T1 - Fluoroquinolone resistance and clinical characteristics of acute bacterial prostatitis in Japan
T2 - A multicenter study by the Japanese research group for urinary tract infection
AU - Matsumoto, Masahiro
AU - Hamasuna, Ryoichi
AU - Wada, Koichiro
AU - Sadahira, Takuya
AU - Shigemura, Katsumi
AU - Maeda, Kouki
AU - Hiyama, Yoshiki
AU - Togo, Yoshikazu
AU - Nagasawa, Seiji
AU - Yamanaka, Kazuaki
AU - Shigehara, Kazuyoshi
AU - Kobayashi, Kanao
AU - Tsuchiya, Haruki
AU - Miyazaki, Jun
AU - Nakagawa, Tohru
AU - Ishikawa, Kiyohito
AU - Takahashi, Satoshi
AU - Fujimoto, Naohiro
AU - Yamamoto, Shingo
N1 - Publisher Copyright:
© 2024 Japanese Society of Chemotherapy, Japanese Association for Infectious Diseases, and Japanese Society for Infection Prevention and Control
PY - 2025/1
Y1 - 2025/1
N2 - Objective: This multicenter study aimed to analyze the risk factors for fluoroquinolone (FQ) resistance and to clarify the clinical characteristics of acute bacterial prostatitis (ABP) in Japan. Methods: A total of 124 patients clinically diagnosed with ABP at 13 medical institutions participating in the Japanese Research Group for Urinary Tract Infection between January and December 2017 were retrospectively reviewed. Results: Of the 124 patients included in this study, 37 were outpatients, and 87 were inpatients. The main underlying medical conditions before the onset of ABP were severe dysuria, urinary retention, transurethral manipulation, indwelling urinary catheter, and transrectal prostate biopsy (TRBx). The main symptoms were fever (≥37.5 °C), prostate tenderness, dysuria, micturition pain, urinary retention, and macrohematuria. Bacteremia was observed in 14 patients. Prostatic abscess was observed in three patients. Escherichia coli was the predominant organism, accounting for 48 % (51/106). FQ-resistant E. coli was detected in 33 % (17/51), and extended-spectrum beta-lactamase-producing E. coli in 12 % (6/51). TRBx (odds ratio [OR] = 48.60, 95 % confidence interval [CI]: 5.49–430.00, p < 0.001) and inpatient status (OR = 29.00, 95 % CI: 1.95–430.00, p = 0.014) were risk factors for the detection of FQ-resistant bacteria. Conclusions: The detection rate of FQ-resistant bacteria was significantly higher with TRBx ABP and inpatient status. These findings have important implications for the management of ABP and antimicrobial treatment, especially for TRBx ABP, which should be considered a separate category.
AB - Objective: This multicenter study aimed to analyze the risk factors for fluoroquinolone (FQ) resistance and to clarify the clinical characteristics of acute bacterial prostatitis (ABP) in Japan. Methods: A total of 124 patients clinically diagnosed with ABP at 13 medical institutions participating in the Japanese Research Group for Urinary Tract Infection between January and December 2017 were retrospectively reviewed. Results: Of the 124 patients included in this study, 37 were outpatients, and 87 were inpatients. The main underlying medical conditions before the onset of ABP were severe dysuria, urinary retention, transurethral manipulation, indwelling urinary catheter, and transrectal prostate biopsy (TRBx). The main symptoms were fever (≥37.5 °C), prostate tenderness, dysuria, micturition pain, urinary retention, and macrohematuria. Bacteremia was observed in 14 patients. Prostatic abscess was observed in three patients. Escherichia coli was the predominant organism, accounting for 48 % (51/106). FQ-resistant E. coli was detected in 33 % (17/51), and extended-spectrum beta-lactamase-producing E. coli in 12 % (6/51). TRBx (odds ratio [OR] = 48.60, 95 % confidence interval [CI]: 5.49–430.00, p < 0.001) and inpatient status (OR = 29.00, 95 % CI: 1.95–430.00, p = 0.014) were risk factors for the detection of FQ-resistant bacteria. Conclusions: The detection rate of FQ-resistant bacteria was significantly higher with TRBx ABP and inpatient status. These findings have important implications for the management of ABP and antimicrobial treatment, especially for TRBx ABP, which should be considered a separate category.
KW - Acute bacterial prostatitis
KW - Antimicrobial treatment
KW - Fluoroquinolone resistance
KW - Inpatient
KW - Transrectal prostate biopsy
UR - http://www.scopus.com/inward/record.url?scp=85201448077&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85201448077&partnerID=8YFLogxK
U2 - 10.1016/j.jiac.2024.08.012
DO - 10.1016/j.jiac.2024.08.012
M3 - Article
C2 - 39151550
AN - SCOPUS:85201448077
SN - 1341-321X
VL - 31
JO - Journal of Infection and Chemotherapy
JF - Journal of Infection and Chemotherapy
IS - 1
M1 - 102497
ER -